Moderate to Severe Asthma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Moderate to Severe Asthma Emerging Therapy and TPP Insights

Thelansis’s “Moderate to Severe Asthma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Moderate to Severe Asthma Overview

Moderate to severe asthma is a heterogeneous chronic airway disease characterized by variable airflow limitation, bronchial hyperresponsiveness, airway inflammation, and, in some patients, structural remodeling. Severe disease can lead to recurrent exacerbations, substantial functional impairment, and high healthcare utilization. Current management is built around inhaled corticosteroid-containing therapy and bronchodilators, with maintenance oral corticosteroids reserved for selected severe cases because of serious systemic toxicity. The treatment landscape has evolved substantially with phenotype-guided biologics targeting IgE, IL-5/IL-5Rα, IL-4Rα, and TSLP, establishing precision therapy for many patients with severe Type 2 asthma. Yet important gaps remain, particularly in non-Type 2 disease, incomplete response, corticosteroid dependence, and the prevention of long-term structural decline. These needs are driving development of upstream epithelial-alarmin approaches such as IL-33/ST2 blockade, multi-pathway strategies, and targeted intracellular therapies, including inhaled JAK1 inhibitors. For stakeholders, the next opportunity in asthma is not simply adding another biologic, but extending precision treatment to broader patient populations while achieving more durable control with less corticosteroid exposure.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)